Q0220 HCPCS code: Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg

Q0220 is the HCPCS Level II code for injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg. CMS terminated Q0220 on 2024-12-12; do not bill it for later dates of service. In 2023 Medicare paid an average of $0.01 per service for Q0220 across 101 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. Medicare volume fell 100% from 2022 to 2023 (27,882 to 101 services). In 2023, about 48 clinicians billed Medicare for Q0220 for 101 beneficiaries.

Code details

FieldValue
SectionQ codes — Temporary codes
Coverage codeC — Carrier judgment
Pricing indicator54
BETOS categoryO1G — Immunizations/vaccinations
Added2021-12-08
Last action effective2024-12-13
Terminated2024-12-12

Who bills Q0220 (2023)

MeasureValue
Clinicians billing (by place of service)48
Medicare beneficiaries101
States with claims4

Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.

Medicare utilization for Q0220, 2022–2023

YearServicesBeneficiariesAvg. allowedAvg. paid
202227,8823,745$0.00$0.00
2023101101$0.01$0.01

States with the most Q0220 services (2023)

StateServicesAvg. paid
Florida16$0.01
Texas13$0.01
California11$0.01
Louisiana11$0.01

What changed for Q0220

Frequently asked questions

What is HCPCS code Q0220?

Q0220 is the HCPCS Level II code for injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg. Short descriptor: "Tixagev and cilgav, 300mg".

How much does Medicare pay for Q0220?

In 2023, the average Medicare payment was $0.01 per service (average allowed $0.01).

Does Medicare cover Q0220?

Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.

Related Q02 codes

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.

All Q codes · HCPCS lookup